JP2019524820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524820A5 JP2019524820A5 JP2019507777A JP2019507777A JP2019524820A5 JP 2019524820 A5 JP2019524820 A5 JP 2019524820A5 JP 2019507777 A JP2019507777 A JP 2019507777A JP 2019507777 A JP2019507777 A JP 2019507777A JP 2019524820 A5 JP2019524820 A5 JP 2019524820A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- seq
- sequence
- hvr
- drug combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000890 drug combination Substances 0.000 claims 13
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 12
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 229940124647 MEK inhibitor Drugs 0.000 claims 7
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 6
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 6
- 229960002271 cobimetinib Drugs 0.000 claims 5
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960003852 atezolizumab Drugs 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374437P | 2016-08-12 | 2016-08-12 | |
| US62/374,437 | 2016-08-12 | ||
| PCT/US2017/046458 WO2018031865A1 (en) | 2016-08-12 | 2017-08-11 | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524820A JP2019524820A (ja) | 2019-09-05 |
| JP2019524820A5 true JP2019524820A5 (enExample) | 2020-09-17 |
Family
ID=59700207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507777A Pending JP2019524820A (ja) | 2016-08-12 | 2017-08-11 | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤及びｖｅｇｆ阻害剤での組合せ療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190161549A1 (enExample) |
| EP (1) | EP3496752B1 (enExample) |
| JP (1) | JP2019524820A (enExample) |
| KR (1) | KR20190038829A (enExample) |
| CN (1) | CN109689102A (enExample) |
| AU (1) | AU2017311585A1 (enExample) |
| BR (1) | BR112019002036A2 (enExample) |
| CA (1) | CA3032542A1 (enExample) |
| MX (1) | MX2019001635A (enExample) |
| TW (1) | TW201811369A (enExample) |
| WO (1) | WO2018031865A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| AR107303A1 (es) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit |
| WO2018065938A1 (en) * | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| DE69832970T2 (de) | 1997-04-07 | 2006-08-10 | Genentech, Inc., South San Francisco | Humanisierte antikörper und verfahren zu ihrer herstellung |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CN103524392B (zh) | 2005-10-07 | 2018-06-01 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶 |
| US8146000B1 (en) | 2005-10-07 | 2012-03-27 | Goodwell Technologies, Inc. | Integrated transactional workflows distributed across multiple contact centers |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| JP6312659B2 (ja) * | 2012-05-31 | 2018-04-18 | ジェネンテック， インコーポレイテッド | Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法 |
| JP6335169B2 (ja) | 2012-08-17 | 2018-05-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法 |
| HRP20180670T1 (hr) | 2012-10-12 | 2018-07-13 | Exelixis Inc. | Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka |
| WO2016061142A1 (en) * | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| HK1251474A1 (zh) * | 2015-06-08 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法 |
-
2017
- 2017-08-11 CN CN201780056198.7A patent/CN109689102A/zh active Pending
- 2017-08-11 TW TW106127203A patent/TW201811369A/zh unknown
- 2017-08-11 BR BR112019002036A patent/BR112019002036A2/pt not_active Application Discontinuation
- 2017-08-11 AU AU2017311585A patent/AU2017311585A1/en not_active Abandoned
- 2017-08-11 CA CA3032542A patent/CA3032542A1/en not_active Abandoned
- 2017-08-11 MX MX2019001635A patent/MX2019001635A/es unknown
- 2017-08-11 WO PCT/US2017/046458 patent/WO2018031865A1/en not_active Ceased
- 2017-08-11 KR KR1020197003739A patent/KR20190038829A/ko not_active Ceased
- 2017-08-11 EP EP17757629.5A patent/EP3496752B1/en active Active
- 2017-08-11 JP JP2019507777A patent/JP2019524820A/ja active Pending
-
2019
- 2019-02-08 US US16/271,290 patent/US20190161549A1/en not_active Abandoned
-
2022
- 2022-04-12 US US17/658,949 patent/US20220298247A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018184417A5 (enExample) | ||
| JP2018108086A5 (enExample) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2013520442A5 (enExample) | ||
| JP2011506483A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| RU2015151454A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АФУКОЗИЛИРОВАННОГО АНТИТЕЛА К CD20 В СОЧЕТАНИИ С КОНЪЮГАТОМ АНТИТЕЛО К CD79b-ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
| JP2015529225A5 (enExample) | ||
| JP2015523380A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2019534251A5 (enExample) | ||
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2003531129A5 (enExample) | ||
| JP2017031160A5 (enExample) | ||
| JP2012509889A5 (enExample) | ||
| JP2022512851A5 (enExample) | ||
| JP2016063817A5 (enExample) | ||
| JP2018507220A5 (enExample) | ||
| JP2017533221A5 (enExample) | ||
| IL319182A (en) | Deuterium-enriched pirfenidone and methods of using it | |
| JP2024533067A5 (enExample) | ||
| RU2015151455A (ru) | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с конъюгатом антитело к cd22-лекарственное средство | |
| JP2021528438A5 (enExample) | ||
| RU2017128616A (ru) | Комбинированное лекарственное средство |